表紙
市場調查報告書

白斑症:開發中產品分析

Vitiligo - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 213131
出版日期 內容資訊 英文 144 Pages
訂單完成後即時交付
價格
白斑症:開發中產品分析 Vitiligo - Pipeline Review, H1 2020
出版日期: 2020年04月30日內容資訊: 英文 144 Pages
簡介

所謂白斑症,是皮膚失去黑色素(皮膚、頭髮、眼睛顏色的色素)的疾病。主要的症狀,為少年白頭(少年、青年時期,頭髮、眉毛、睫毛、鬍鬚變成白色、灰色),及口腔內部的組織脫色,視網膜的脫色、變色等。主要的治療方法,有皮質類固醇療法和免疫調節藥物,外科手術等。

本報告提供全球各國的白斑症治療用的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

簡介

  • 調查範圍

白斑症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品:各企業
  • 企業開發中的產品

白斑症:治療藥的評估

  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

白斑症的開發治療藥的企業

  • Aclaris Therapeutics Inc
  • Arrien Pharmaceuticals LLC
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • Clinuvel Pharmaceuticals Ltd
  • Incyte Corp

藥物簡介

白斑症:暫停中的計劃

白斑症:產品開發里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC12124IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vitiligo - Pipeline Review, H1 2020, provides an overview of the Vitiligo (Dermatology) pipeline landscape.

Vitiligo is a condition in which skin loses melanin, the pigment that determines the color of skin, hair and eyes. Symptoms include premature whitening or graying of the hair on scalp, eyelashes, eyebrows or beard, loss of color in the tissues that line the inside of mouth and loss of or change in color of the inner layer of eye. Treatment includes corticosteroid therapy, immunomodulators and surgery.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vitiligo - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Vitiligo (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vitiligo (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Vitiligo and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 2, 9 and 3 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Vitiligo (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Vitiligo (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Vitiligo (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Vitiligo (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Vitiligo (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Vitiligo (Dermatology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Vitiligo (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Vitiligo (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Vitiligo - Overview
  • Vitiligo - Therapeutics Development
  • Vitiligo - Therapeutics Assessment
  • Vitiligo - Companies Involved in Therapeutics Development
  • Vitiligo - Drug Profiles
  • Vitiligo - Dormant Projects
  • Vitiligo - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Vitiligo, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Vitiligo - Pipeline by 2A Pharma AB, H1 2020
  • Vitiligo - Pipeline by Aclaris Therapeutics Inc, H1 2020
  • Vitiligo - Pipeline by Amgen Inc, H1 2020
  • Vitiligo - Pipeline by AnTolRx Inc, H1 2020
  • Vitiligo - Pipeline by Arrien Pharmaceuticals LLC, H1 2020
  • Vitiligo - Pipeline by Boston Pharmaceuticals Inc, H1 2020
  • Vitiligo - Pipeline by Bristol-Myers Squibb Co, H1 2020
  • Vitiligo - Pipeline by Castle Creek Biosciences Inc, H1 2020
  • Vitiligo - Pipeline by Clinuvel Pharmaceuticals Ltd, H1 2020
  • Vitiligo - Pipeline by Incyte Corp, H1 2020
  • Vitiligo - Pipeline by Innovision Therapeutics Inc, H1 2020
  • Vitiligo - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020
  • Vitiligo - Pipeline by JN Biosciences LLC, H1 2020
  • Vitiligo - Pipeline by Pfizer Inc, H1 2020
  • Vitiligo - Pipeline by Portola Pharmaceuticals Inc, H1 2020
  • Vitiligo - Pipeline by Radikal Therapeutics Inc, H1 2020
  • Vitiligo - Pipeline by Rheos Medicines Inc, H1 2020
  • Vitiligo - Pipeline by Temprian Therapeutics Inc, H1 2020
  • Vitiligo - Pipeline by Villaris Therapeutics Inc, H1 2020
  • Vitiligo - Dormant Projects, H1 2020

List of Figures

  • Number of Products under Development for Vitiligo, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020